JP2005506334A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005506334A5 JP2005506334A5 JP2003532491A JP2003532491A JP2005506334A5 JP 2005506334 A5 JP2005506334 A5 JP 2005506334A5 JP 2003532491 A JP2003532491 A JP 2003532491A JP 2003532491 A JP2003532491 A JP 2003532491A JP 2005506334 A5 JP2005506334 A5 JP 2005506334A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutical composition
- composition according
- conh
- thiophene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32697601P | 2001-10-04 | 2001-10-04 | |
| PCT/US2002/031902 WO2003029242A1 (en) | 2001-10-04 | 2002-10-04 | NF-λB INHIBITORS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005506334A JP2005506334A (ja) | 2005-03-03 |
| JP2005506334A5 true JP2005506334A5 (enExample) | 2006-01-05 |
Family
ID=23274589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003532491A Pending JP2005506334A (ja) | 2001-10-04 | 2002-10-04 | ＮＦ−κＢ阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7166639B2 (enExample) |
| EP (1) | EP1448545B1 (enExample) |
| JP (1) | JP2005506334A (enExample) |
| AT (1) | ATE414697T1 (enExample) |
| DE (1) | DE60229975D1 (enExample) |
| ES (1) | ES2315430T3 (enExample) |
| WO (1) | WO2003029242A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0003154D0 (en) * | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
| PL395097A1 (pl) * | 2001-06-11 | 2011-10-10 | Vertex Pharmaceuticals (Canada) Incorporated | Sposób wytwarzania związku o wzorze A stanowiącego pochodną tiofenu |
| SE0102616D0 (sv) * | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| TW200403991A (en) | 2002-04-11 | 2004-03-16 | Smithkline Beecham Corp | NF-κb inhibitors |
| JP2005531608A (ja) * | 2002-06-06 | 2005-10-20 | スミスクライン・ビーチャム・コーポレイション | ＮＦ−κＢ阻害剤 |
| SE0202279D0 (sv) * | 2002-07-19 | 2002-07-19 | Astrazeneca Ab | Novel comppounds |
| SE0202280D0 (sv) * | 2002-07-19 | 2002-07-19 | Astrazeneca Ab | Novel compounds |
| US7199119B2 (en) | 2002-10-31 | 2007-04-03 | Amgen Inc. | Antiinflammation agents |
| JP2006510676A (ja) * | 2002-12-06 | 2006-03-30 | スミスクライン・ビーチャム・コーポレイション | ＮＦ−κＢ阻害剤 |
| ES2345438T3 (es) * | 2002-12-10 | 2010-09-23 | Virochem Pharma Inc. | Compuestos y metodos para el tratamiento o prevencion de infecciones por flavivirus. |
| SE0300091D0 (sv) * | 2003-01-15 | 2003-01-15 | Astrazeneca Ab | Novel compounds |
| SE0300092D0 (sv) * | 2003-01-15 | 2003-01-15 | Astrazeneca Ab | Novel compounds |
| BRPI0413585A (pt) | 2003-08-15 | 2006-10-17 | Astrazeneca Ab | composto ou sal farmaceuticamente aceitável ou um precursor hidrolisável in vivo deste, uso de um composto ou um sal deste farmaceuticamente aceitável, métodos para o tratamento de cáncer, e de infecções associadas com cáncer, composição farmacêutica, e, processo para preparação e uso de um composto ou um sal farmacêuticamente aceitável ou um precursor hidrolisável in vivo |
| JP4557984B2 (ja) * | 2003-12-05 | 2010-10-06 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | Ｉｋｋインヒビターとしての置換３−アミノ−チエノ−［２，３−ｂ］ピリジン−２−カルボン酸アミド化合物 |
| DE602004031777D1 (en) * | 2004-01-05 | 2011-04-21 | Astrazeneca Ab | Thiophenderivate als chk-1-inhibitoren |
| GB0402809D0 (en) * | 2004-02-09 | 2004-03-10 | Glaxo Group Ltd | Chemical compounds |
| TW200609237A (en) * | 2004-04-12 | 2006-03-16 | Sankyo Co | Thienopyridine derivatives |
| AR056645A1 (es) | 2005-03-29 | 2007-10-17 | Icos Corp | Compuestos de urea sustituida inhibidores de enzimas chk1 . |
| EP2546246A3 (en) | 2005-05-13 | 2013-04-24 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
| JP2009526855A (ja) | 2006-02-16 | 2009-07-23 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | アルファカルボリンおよびその使用 |
| EA201101492A1 (ru) | 2006-11-15 | 2012-09-28 | Вирокем Фарма Инк. | Аналоги тиофена для лечения или предупреждения флавивирусных инфекций |
| US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
| EP2278999B1 (en) | 2008-04-21 | 2025-01-29 | Dompé farmaceutici S.p.A. | Auris formulations for treating otic diseases and conditions |
| JP2010006717A (ja) * | 2008-06-24 | 2010-01-14 | Kyorin Pharmaceut Co Ltd | ジヒドロチエノ［２，３−ｅ］インダゾール化合物 |
| AU2009298981B2 (en) | 2008-10-02 | 2012-09-27 | Asahi Kasei Pharma Corporation | 8-substituted isoquinoline derivative and use thereof |
| US20100137246A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Anti-inflammatory compositions and methods |
| US20100136096A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
| US20100136094A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
| US20100137247A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Anti-inflammatory compositions and methods |
| US20100135983A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Anti-inflammatory compositions and methods |
| US20100136095A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
| US20100135984A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Anti-inflammatory compositions and methods |
| WO2011077502A1 (ja) * | 2009-12-21 | 2011-06-30 | 杏林製薬株式会社 | ジヒドロチエノ［２，３－ｅ］インダゾール化合物 |
| EP2520292A1 (en) | 2011-05-06 | 2012-11-07 | Helmholtz-Zentrum für Infektionsforschung GmbH | Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders |
| US20150167097A1 (en) | 2012-09-20 | 2015-06-18 | Emory University | CLASSIFIERS OF NF-kB PATHWAY ACTIVATION, DEVICES, AND METHODS OF USE THEREOF |
| WO2018005830A1 (en) | 2016-06-29 | 2018-01-04 | Otonomy, Inc. | Triglyceride otic formulations and uses thereof |
| WO2019012159A1 (en) | 2017-07-14 | 2019-01-17 | Protea Biopharma N.V. | METHODS AND MEANS FOR DIAGNOSING AND / OR TREATING A FATIGUE-ASSOCIATED DISEASE |
| CA3073810A1 (en) * | 2017-08-31 | 2019-03-07 | Ahammune Biosciences Private Limited | Thiophene-derived compounds, process for synthesis and use thereof |
| CN115161289B (zh) * | 2022-03-14 | 2023-12-05 | 东南大学 | 一种用于炎症性疾病治疗的重组腺相关病毒及其构建方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1468012A (en) * | 1973-08-09 | 1977-03-23 | Beecham Group Ltd | 2-amino-3-carboxy-thiophene derivatives |
| DE4039734A1 (de) * | 1990-12-13 | 1992-06-17 | Basf Ag | Substituierte 2-aminothiophene enthaltende herbizide mittel |
| US6274590B1 (en) * | 1993-01-15 | 2001-08-14 | G. D. Searle & Co. | Method of treating skin related conditions |
| DE19642451A1 (de) * | 1996-10-15 | 1998-04-16 | Merck Patent Gmbh | Aminothiophencarbonsäureamide |
| WO2000002851A1 (en) * | 1998-07-08 | 2000-01-20 | Aventis Pharma Deutschland Gmbh | Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| GB0003154D0 (en) * | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
| US6414013B1 (en) * | 2000-06-19 | 2002-07-02 | Pharmacia & Upjohn S.P.A. | Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention |
| AU2002211663A1 (en) | 2000-10-12 | 2002-04-22 | Smith Kline Beecham Corporation | Nf-$g(k)b inhibitors |
| US6713638B2 (en) * | 2001-05-18 | 2004-03-30 | Joel M. Linden | 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors |
| PL395097A1 (pl) * | 2001-06-11 | 2011-10-10 | Vertex Pharmaceuticals (Canada) Incorporated | Sposób wytwarzania związku o wzorze A stanowiącego pochodną tiofenu |
| SE0102617D0 (sv) * | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| US6835745B2 (en) * | 2002-01-15 | 2004-12-28 | Wyeth | Phenyl substituted thiophenes as estrogenic agents |
| US7084178B2 (en) * | 2003-11-26 | 2006-08-01 | Bristol-Myers Squibb Company | Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives |
-
2002
- 2002-10-04 JP JP2003532491A patent/JP2005506334A/ja active Pending
- 2002-10-04 ES ES02800491T patent/ES2315430T3/es not_active Expired - Lifetime
- 2002-10-04 EP EP02800491A patent/EP1448545B1/en not_active Expired - Lifetime
- 2002-10-04 WO PCT/US2002/031902 patent/WO2003029242A1/en not_active Ceased
- 2002-10-04 DE DE60229975T patent/DE60229975D1/de not_active Expired - Lifetime
- 2002-10-04 AT AT02800491T patent/ATE414697T1/de not_active IP Right Cessation
- 2002-10-04 US US10/491,710 patent/US7166639B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005506334A5 (enExample) | ||
| JP2006510676A5 (enExample) | ||
| CN100415724C (zh) | 嘧啶衍生物 | |
| JP2019131569A5 (enExample) | ||
| JP2004535466A5 (enExample) | ||
| JP2007522142A5 (enExample) | ||
| JP2008504363A5 (enExample) | ||
| JP2017514839A5 (enExample) | ||
| JP2018150331A5 (enExample) | ||
| ES2407807T3 (es) | Derivados de tiazolilo 2-amino-4,5-trisustituidos y su uso frente a enfermedades autoinmunitarias | |
| JP2006514626A5 (enExample) | ||
| JP2008543860A5 (enExample) | ||
| JP2012255002A5 (enExample) | ||
| EP3654987B1 (en) | Use of aminoalkylbenzothiazepine derivatives | |
| CA2556463C (en) | Dihydropyridinone derivatives | |
| JP2008512490A5 (enExample) | ||
| JP2008501637A5 (enExample) | ||
| JP2010526814A5 (enExample) | ||
| JP2013517283A5 (enExample) | ||
| JP2008531537A5 (enExample) | ||
| JP2008513499A5 (enExample) | ||
| JP2005501012A5 (enExample) | ||
| AU2020354138B2 (en) | Heteroarylamidopyridinol derivative and pharmaceutical composition comprising same as active ingredient for prevention or treatment of autoimmune disease | |
| JP2005508955A5 (enExample) | ||
| JP2008500999A5 (enExample) |